콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

Y0002098

Sorafenib

European Pharmacopoeia (EP) Reference Standard

동의어(들):

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C21H16ClF3N4O3
CAS Number:
284461-73-0
Molecular Weight:
464.82
MDL number:
MFCD06411450
UNSPSC 코드:
41116107
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

sorafenib

제조업체/상표

EDQM

응용 분야

pharmaceutical

형식

neat

저장 온도

2-8°C

SMILES string

FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

InChI key

MLDQJTXFUGDVEO-UHFFFAOYSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Sorafenib EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

픽토그램

Health hazardEnvironment
GHS08,GHS09

신호어

Danger

유해 및 위험 성명서

H360FD,H362,H372,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

Storage Class Code

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Zhong Wan et al.
Aging, 12(18), 18192-18208 (2020-10-07)
We investigated MAPK14-dependent resistance to sorafenib in hepatocellular carcinoma (HCC). Bioinformatics analysis and dual luciferase reporter assays in HCC cell lines showed that miR-216a-3p directly binds to the 3'UTR of MAPK14 mRNA and downregulates MAPK14 protein expression. Consequently, miR-216a-3p expression
Baoxin Zhao et al.
Virologica Sinica, 38(5), 680-689 (2023-06-19)
Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC). The HBV genome is prone to mutate and several variants are closely related to the malignant transformation of liver disease. G1896A mutation (G to
Yiliang Wang et al.
Journal of nanobiotechnology, 22(1), 473-473 (2024-08-13)
Hepatocellular carcinoma (HCC) is a highly malignant tumor known for its hypoxic environment, which contributes to resistance against the anticancer drug Sorafenib (SF). Addressing SF resistance in HCC requires innovative strategies to improve tumor oxygenation and effectively deliver therapeutics. In
Ye Kuang et al.
Cancer medicine, 12(6), 7222-7233 (2022-11-25)
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long-term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is
Su-Hong Chen et al.
Experimental and therapeutic medicine, 23(3), 232-232 (2022-03-01)
Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.